WO2004014951A3 - Molecules de liaison - Google Patents

Molecules de liaison Download PDF

Info

Publication number
WO2004014951A3
WO2004014951A3 PCT/EP2003/008651 EP0308651W WO2004014951A3 WO 2004014951 A3 WO2004014951 A3 WO 2004014951A3 EP 0308651 W EP0308651 W EP 0308651W WO 2004014951 A3 WO2004014951 A3 WO 2004014951A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding molecules
side chain
chain subunits
unnatural
natural
Prior art date
Application number
PCT/EP2003/008651
Other languages
English (en)
Other versions
WO2004014951A2 (fr
Inventor
Udo Haberl
Christian Frosch
Hans-Georg Frank
Andreas Rybka
Raimund Wieser
Original Assignee
Aplagen Gmbh
Udo Haberl
Christian Frosch
Hans-Georg Frank
Andreas Rybka
Raimund Wieser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02017525A external-priority patent/EP1394180B1/fr
Application filed by Aplagen Gmbh, Udo Haberl, Christian Frosch, Hans-Georg Frank, Andreas Rybka, Raimund Wieser filed Critical Aplagen Gmbh
Priority to CA002493019A priority Critical patent/CA2493019A1/fr
Priority to AU2003253381A priority patent/AU2003253381A1/en
Priority to EP03784178A priority patent/EP1527096A2/fr
Priority to JP2004526881A priority patent/JP4667868B2/ja
Publication of WO2004014951A2 publication Critical patent/WO2004014951A2/fr
Publication of WO2004014951A3 publication Critical patent/WO2004014951A3/fr
Priority to IL166361A priority patent/IL166361A/en
Priority to US11/389,667 priority patent/US20070060508A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Abstract

L'invention concerne des molécules de liaison constituées d'une structure porteuse d'au moins une sous-unité moléculaire cyclique et d'au moins deux sous-unités à chaînes latérales. Lesdites sous-unités à chaînes latérales sont des chaînes polypeptidiques constituées d'acides D- et/ou L-aminés naturels et/ou non naturels, les sous-unités de chaîne latérale étant liées de manière covalente à la structure de support.
PCT/EP2003/008651 2002-08-06 2003-08-05 Molecules de liaison WO2004014951A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002493019A CA2493019A1 (fr) 2002-08-06 2003-08-05 Molecules de liaison
AU2003253381A AU2003253381A1 (en) 2002-08-06 2003-08-05 Binding molecules
EP03784178A EP1527096A2 (fr) 2002-08-06 2003-08-05 Molecules de liaison
JP2004526881A JP4667868B2 (ja) 2002-08-06 2003-08-05 結合分子
IL166361A IL166361A (en) 2002-08-06 2005-01-18 Binding molecules
US11/389,667 US20070060508A1 (en) 2002-08-06 2006-03-27 Binding molecules

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40103202P 2002-08-06 2002-08-06
US60/401,032 2002-08-06
EP02017525.3 2002-08-06
EP02017525A EP1394180B1 (fr) 2002-08-06 2002-08-06 Molécules synthétiques mimetiques de molécules de liason physiologiques
EP03010892 2003-05-15
EP03010892.2 2003-05-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10523716 A-371-Of-International 2003-08-05
US11/389,667 Continuation US20070060508A1 (en) 2002-08-06 2006-03-27 Binding molecules

Publications (2)

Publication Number Publication Date
WO2004014951A2 WO2004014951A2 (fr) 2004-02-19
WO2004014951A3 true WO2004014951A3 (fr) 2004-07-22

Family

ID=56290465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008651 WO2004014951A2 (fr) 2002-08-06 2003-08-05 Molecules de liaison

Country Status (6)

Country Link
EP (1) EP1527096A2 (fr)
JP (1) JP4667868B2 (fr)
CN (1) CN1675243A (fr)
AU (1) AU2003253381A1 (fr)
CA (1) CA2493019A1 (fr)
WO (1) WO2004014951A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1616957B1 (fr) * 2003-04-18 2017-05-17 National Cerebral and Cardiovascular Center Vecteur
MXPA05012072A (es) * 2003-05-23 2006-02-22 Aplagen Gmbh Complejos de quelatos de metal inmovilizados sobre soportes solidos para la preparacion de peptidos.
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
EP4269422A1 (fr) * 2020-12-25 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Procédé de production d'un composé peptidique contenant un résidu d'acide aminé n-substitué

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021206A1 (fr) * 1992-04-08 1993-10-28 The Scripps Research Institute Polypeptides synthetiques tridimensionnels stabilises
WO1998020036A1 (fr) * 1996-11-06 1998-05-14 Genentech, Inc. Peptide a structure helicoidale contrainte et leurs procedes de fabrication
WO2000004048A1 (fr) * 1998-07-16 2000-01-27 Institut Pasteur Peptides d'yl-2 et leurs derives et leur utilisation comme agents therapeutiques
WO2000024782A2 (fr) * 1998-10-23 2000-05-04 Amgen Inc. Peptides modifies utilises comme agents therapeutiques
US6096710A (en) * 1995-11-17 2000-08-01 The Regents Of The University Of California Collagen-like peptoid residue-containing structures
WO2001011050A1 (fr) * 1999-08-04 2001-02-15 Amgen Inc. Fhm, NOUVEAU MEMBRE DE LA FAMILLE DES SUPERGENES LIGANDS DU TNF__

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021206A1 (fr) * 1992-04-08 1993-10-28 The Scripps Research Institute Polypeptides synthetiques tridimensionnels stabilises
US6096710A (en) * 1995-11-17 2000-08-01 The Regents Of The University Of California Collagen-like peptoid residue-containing structures
WO1998020036A1 (fr) * 1996-11-06 1998-05-14 Genentech, Inc. Peptide a structure helicoidale contrainte et leurs procedes de fabrication
WO2000004048A1 (fr) * 1998-07-16 2000-01-27 Institut Pasteur Peptides d'yl-2 et leurs derives et leur utilisation comme agents therapeutiques
WO2000024782A2 (fr) * 1998-10-23 2000-05-04 Amgen Inc. Peptides modifies utilises comme agents therapeutiques
WO2001011050A1 (fr) * 1999-08-04 2001-02-15 Amgen Inc. Fhm, NOUVEAU MEMBRE DE LA FAMILLE DES SUPERGENES LIGANDS DU TNF__

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
APPELHANS ET AL.: "Synthesis and characterization of poly(ether amide) dendrimers containing different core molecules", MACROMOLECULES, vol. 33, 2000, pages 9494 - 9503, XP002259018 *
CIARDELLI T L ET AL: "Structural studies of interleukin 2", PEPTIDES. STRUCTURE & FUNCTION, PROCEEDINGS OF THE AMERICAN PEPTIDE SYMPOSIUM, ROCKFORD, PIERCE CHEMICAL CO, US, vol. PROC. 9, 1985, pages 75 - 78, XP002100685 *
FUJII H ET AL: "ANTIMETASTATIC ACTVITIES OF SYNTHETIC ARG-GLY-ASP-SER (RGDS) AND ARG-LEU-ASP-SER (RLDS) PEPTIDE ANALOGUES AND THEIR INHIBITORY MECHANISMS", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 18, no. 12, December 1995 (1995-12-01), pages 1681 - 1688, XP001108987, ISSN: 0918-6158 *
RANGANATHAN D ET AL: "DESIGN AND SYNTHESIS OF AB3-TYPE (A=1,3,5-BENZENETRICARBONYL UNIT;B=GLU DIOME OR GLU7 OCTA OME) PEPTIDE DENDRIMERS: CRYSTAL STRUCTURE OF THE FIRST GENERATION", BIOPOLYMERS, NEW YORK, NY, US, vol. 54, no. 4, 2000, pages 289 - 295, XP001040555, ISSN: 0006-3525 *

Also Published As

Publication number Publication date
JP2006513980A (ja) 2006-04-27
AU2003253381A1 (en) 2004-02-25
CA2493019A1 (fr) 2004-02-19
EP1527096A2 (fr) 2005-05-04
WO2004014951A2 (fr) 2004-02-19
JP4667868B2 (ja) 2011-04-13
CN1675243A (zh) 2005-09-28

Similar Documents

Publication Publication Date Title
EP1329458A3 (fr) Peptides abaissant le taux de glucose sanguin
WO2006081249A3 (fr) Conjugues de proteine biologiquement actives possedant une demi-vie in vivo modifiee
ATE413415T1 (de) Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate
EP2949658A3 (fr) Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées
ATE551352T1 (de) Peptidakzeptorbindungsverfahren
EP1454138A4 (fr) Immunocytokines a selectivite modulee
WO2005012364A3 (fr) Matrice complexe a usage biomedical
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
WO2004108070A3 (fr) Conjugues polymeres liberables fondes sur des lieurs biodegradables aliphatiques
WO1998046257A8 (fr) Compositions comprenant des conjugues de proteine ob humaine, active, stable avec une chaine fc d'anticorps et leurs procedes
AU2001290312A1 (en) Peg-modified erythropoietin
PT938502E (pt) Metodo selectivo por acilacao
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
EP1967590A3 (fr) Constructions d'emballages lentivirus
WO2004044222A3 (fr) Promedicaments polymeres de la vancomycine
WO2004014951A3 (fr) Molecules de liaison
WO2003053473A3 (fr) Conjugues polymeres sensibles au ph d'un cancerostatique a base d'antracycline pour therapie ciblee
WO2004044223A3 (fr) Promedicaments de vancomycine comportant des liants polymeres resistant a l'hydrolyse
WO2004083245A3 (fr) Agent
EP1806367A3 (fr) Polymères contenant des polysaccharides tels que les alginates ou les alginates modifiés
DE60313786D1 (de) Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4
ATE433960T1 (de) Photoaktivierbare aminosäuren
WO2003093300A3 (fr) Peptides anti-microbiens et compositions
GEP20084464B (en) Mutated neublastin
WO2004029280A3 (fr) Dosage biologique anti-hla et procedes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003253381

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2493019

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20038185474

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003784178

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200501049

Country of ref document: ZA

Ref document number: 2004526881

Country of ref document: JP

Ref document number: 1020057002117

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005106244

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2003784178

Country of ref document: EP

Ref document number: 1020057002117

Country of ref document: KR